We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $141.98, moving -2.39% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.02% for the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.15%.
Shares of the pharmaceutical company have appreciated by 0.41% over the course of the past month, underperforming the Medical sector's gain of 1.06%, and the S&P 500's gain of 2.05%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 29, 2026. On that day, Merck is projected to report earnings of $2.12 per share, which would represent a year-over-year decline of 17.83%. At the same time, our most recent consensus estimate is projecting a revenue of $17.23 billion, reflecting a 0.25% fall from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.66 per share and a revenue of $67.1 billion, representing changes of -70.38% and +3.21%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.83% decrease. Currently, Merck is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Merck is presently being traded at a Forward P/E ratio of 54.73. This represents a premium compared to its industry average Forward P/E of 16.15.
We can additionally observe that MRK currently boasts a PEG ratio of 6.72. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.92.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 208, putting it in the bottom 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Dips More Than Broader Market: What You Should Know
Merck (MRK - Free Report) closed the most recent trading day at $141.98, moving -2.39% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.02% for the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.15%.
Shares of the pharmaceutical company have appreciated by 0.41% over the course of the past month, underperforming the Medical sector's gain of 1.06%, and the S&P 500's gain of 2.05%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 29, 2026. On that day, Merck is projected to report earnings of $2.12 per share, which would represent a year-over-year decline of 17.83%. At the same time, our most recent consensus estimate is projecting a revenue of $17.23 billion, reflecting a 0.25% fall from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.66 per share and a revenue of $67.1 billion, representing changes of -70.38% and +3.21%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.83% decrease. Currently, Merck is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Merck is presently being traded at a Forward P/E ratio of 54.73. This represents a premium compared to its industry average Forward P/E of 16.15.
We can additionally observe that MRK currently boasts a PEG ratio of 6.72. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.92.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 208, putting it in the bottom 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.